For immediate release |
18 March 2013 |
("Alliance" or the "Company")
Major Interest in Shares
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was today informed that, on 15 March 2013, Nigel Wray purchased 885,000 ordinary shares of 1p each in the Company.
Mr Wray's resultant holding is 36,926,995 ordinary shares, equivalent to 15.07% of the Company's issued share capital.
Mr Wray's ordinary shares are held as follows:
Nominee |
Number of ordinary shares |
Pershing Nominees Limited Roy Nominees Limited
|
12,262,407 24,664,588 |
For further information:
Alliance Pharma plc |
+ 44 (0) 1249 466966 |
John Dawson, Chief Executive |
|
Richard Wright, Finance Director |
|
|
|
Buchanan |
+ 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
|
|
|
Numis Securities Limited |
+ 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Oliver Cardigan |
|
Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.